Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Epigenetics
|
May 20, 2008
A work in progress: the clinical development of histone deacetylase inhibitors
Silvia Marsoni, Giovanna Damia, Gabriella Camboni
Journal of Cellular and Molecular Medicine
|
July 19, 2012
Is PDGFR an important target for E-3810?
Giovanna Damia, Gennaro Colella, Gabriella Camboni, et al.
Journal of Mass Spectrometry : JMS
|
January 22, 2014
HPLC-MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E-3810 in tumor tissues from xenograft mice and human biopsies
Monique Zangarini, Laura Ceriani, Ezia Bello, et al.
Anti-Cancer Drugs
|
August 19, 2006
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
Thomas A Hensing, Nasser H Hanna, Heidi H Gillenwater, et al.
Cancer Chemotherapy and Pharmacology
|
November 8, 2003
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer
Charlie Gourley, James Cassidy, Chris Edwards, et al.
Cancer Research
|
January 8, 2011
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models
Ezia Bello, Gennaro Colella, Valentina Scarlato, et al.
Haematologica
|
August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas
Peter Borchmann, Franck Morschhauser, Anne Parry, et al.
Molecular Cancer Therapeutics
|
December 29, 2012
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts
Ezia Bello, Giulia Taraboletti, Gennaro Colella, et al.
Pharmacological Research
|
August 9, 2025
Targeting of the IGFBP3/TMEM219 pathway restores intestinal stem cells capability of healing mucosa in gastrointestinal autoimmune disorders
Giovanni Amabile, Francesca D'Addio, Anna Maestroni, et al.
Nature Communications
|
February 4, 2022
The IGFBP3/TMEM219 pathway regulates beta cell homeostasis
Francesca D'Addio, Anna Maestroni, Emma Assi, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Epigenetics
|
May 20, 2008
A work in progress: the clinical development of histone deacetylase inhibitors
Silvia Marsoni, Giovanna Damia, Gabriella Camboni
Journal of Cellular and Molecular Medicine
|
July 19, 2012
Is PDGFR an important target for E-3810?
Giovanna Damia, Gennaro Colella, Gabriella Camboni, et al.
Journal of Mass Spectrometry : JMS
|
January 22, 2014
HPLC-MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E-3810 in tumor tissues from xenograft mice and human biopsies
Monique Zangarini, Laura Ceriani, Ezia Bello, et al.
Anti-Cancer Drugs
|
August 19, 2006
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
Thomas A Hensing, Nasser H Hanna, Heidi H Gillenwater, et al.
Cancer Chemotherapy and Pharmacology
|
November 8, 2003
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer
Charlie Gourley, James Cassidy, Chris Edwards, et al.
Cancer Research
|
January 8, 2011
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models
Ezia Bello, Gennaro Colella, Valentina Scarlato, et al.
Haematologica
|
August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas
Peter Borchmann, Franck Morschhauser, Anne Parry, et al.
Molecular Cancer Therapeutics
|
December 29, 2012
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts
Ezia Bello, Giulia Taraboletti, Gennaro Colella, et al.
Pharmacological Research
|
August 9, 2025
Targeting of the IGFBP3/TMEM219 pathway restores intestinal stem cells capability of healing mucosa in gastrointestinal autoimmune disorders
Giovanni Amabile, Francesca D'Addio, Anna Maestroni, et al.
Nature Communications
|
February 4, 2022
The IGFBP3/TMEM219 pathway regulates beta cell homeostasis
Francesca D'Addio, Anna Maestroni, Emma Assi, et al.
Page
of 1